Trial reportEuropean journal of nuclear medicine and molecular imaging2019
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Trial
- Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- The emerging role of ¹⁸F-NaF PET/CT in osteoporosis: an emphasis on its application for the evaluation and management of lumbar spine osteoporosis.EJNMMI research · 2026Review
- Comparison ofScientific reports · 2025Article
- Article
- Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.European radiology · 2024Article
- Whole-Body MRI in Musculoskeletal Oncology: A Comprehensive Review with Recommendations.Radiology. Imaging cancer · 2023Review
- Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?Frontiers in medicine · 2023Review
- [Frontiers in nuclear medicine · 2023Article
- [Cells · 2022Article
- Imaging of Bone Metastases in Breast Cancer.Seminars in nuclear medicine · 2022Review
- Analysis of Cross-Combinations of Feature Selection and Machine-Learning Classification Methods Based on [Cancers · 2022Article
- Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.Skeletal radiology · 2022Review
- 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.Diagnostics (Basel, Switzerland) · 2021Article
- Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.Frontiers in oncology · 2021Review
- Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: a large population-based study.American journal of translational research · 2021Article
- Imaging with radiolabelled bisphosphonates.Bone · 2020Article
- Application of PET Tracers in Molecular Imaging for Breast Cancer.Current oncology reports · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo compare [ PATIENTS AND
methodsThirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUV
resultsTwenty-two patients (median age, 58.6 years, range, 40-79 years) completing baseline and 8-week imaging were included in the final analysis. Per-patient % change in NaF SUV
conclusionsFDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.